To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

1. The patient or their legal guardian understands and voluntarily signs the informed consent form and is expected to complete the follow-up examinations and treatments.

Alanine transaminase (ALT) ≤3 times the upper limit of normal (ULN);

Aspartate transaminase (AST) ≤3 times ULN;

Total bilirubin ≤1.5 times ULN;